Quick answer
Retatrutide is not available in the UK as of June 2026 — it has no MHRA approval and no GPhC-registered provider can supply it. No confirmed UK launch date has been published. While you wait, the Wegovy tablet (oral semaglutide) is approved from £64/month — speak to your prescriber.
When will retatrutide be available in the UK?
Retatrutide — Eli Lilly’s triple GLP-1/GIP/glucagon agonist — generated some of the most striking weight loss trial results seen in obesity medicine. This page tracks where it sits in the regulatory pipeline and what needs to happen before UK patients can access it through a legitimate clinical pathway.
Current status: not available in the UK
As of June 2026, retatrutide has not received MHRA approval for use in the United Kingdom. No GPhC-registered pharmacy or online clinic is authorised to supply it. The drug is available in grey-market form as a “research peptide” but we do not link to or endorse these sources — they are unregulated, unsupervised and outside any legitimate medical supply chain.
Where retatrutide is in its development
Retatrutide has completed phase 3 trials under Eli Lilly’s TRIUMPH programme. Phase 3 data, required for regulatory submission, were reported in 2025. The regulatory submission and review process then determines when approved use begins.
The path to UK availability
For retatrutide to become legally available in the UK for clinical weight management, the following must occur:
- Regulatory submission: Eli Lilly submits a Marketing Authorisation Application to the MHRA (and/or the FDA in the US, typically first). This submission contains all phase 3 trial data, safety information, manufacturing details and proposed prescribing guidance.
- Regulatory review: The MHRA conducts an independent scientific assessment. Standard review is approximately 210 days from submission, though accelerated pathways exist for medicines addressing significant unmet need.
- MHRA approval: A Marketing Authorisation is granted. The drug can then be imported, distributed and prescribed in the UK.
- NHS pricing and access: For NHS coverage, a NICE technology appraisal and commercial agreement with NHS England would be required. This process adds months to years. Private prescription access through online clinics typically comes first.
- Provider listings: UK pharmacies and online clinics begin listing retatrutide for private prescription. This is the point at which it would appear on our tracker.
Expected timeline
UK regulatory approval has historically followed US FDA approval by six months to two or more years. Based on where retatrutide sits in the regulatory process as of June 2026, conservative estimates for UK clinical availability range from late 2026 to 2027 — but this is an estimate, not a confirmed date. Eli Lilly has not published a confirmed UK launch timeline.
Why is there such interest in retatrutide?
Retatrutide’s phase 2 trial results — up to 24.2% body weight reduction at 48 weeks — exceeded what had been seen with any previously approved GLP-1 or dual-agonist drug at equivalent timepoints. The triple mechanism (GLP-1 reduces appetite, GIP amplifies the effect, glucagon increases energy expenditure) appears to produce additive rather than simply incremental weight loss. This drove significant media coverage and patient interest well ahead of any UK approval.
Retatrutide vs what’s available now
While waiting for retatrutide, several options are currently available for supervised weight management in the UK:
- Wegovy tablet (oral semaglutide): Available from 5 UK providers from £64/month. An oral tablet — no injections required. See current prices →
- Mounjaro (tirzepatide): Weekly injection, dual GLP-1/GIP agonist, available from multiple UK providers. Not covered on this site.
- Wegovy injection (semaglutide pen): Weekly injection, available from multiple UK providers. Not covered on this site.
Get notified when retatrutide is approved in the UK
We track all pipeline weight loss drugs. Subscribe for an alert when retatrutide receives MHRA approval or any confirmed UK launch date is announced.
Alert me when retatrutide is approved in the UK →
Related pages
Frequently asked questions
When will retatrutide be available in the UK?
No confirmed date. It is not MHRA-approved as of June 2026. We alert subscribers when approval or a launch date is confirmed.
Is retatrutide legal in the UK in 2026?
It is not approved or available through any GPhC-registered provider. Grey-market 'research peptide' sources are unregulated and outside the legitimate medical supply chain.
What's available while I wait for retatrutide?
The Wegovy tablet (oral semaglutide) is approved and available on pre-order from £64/month — an oral option needing no injection. Speak to your prescriber.
Has retatrutide been submitted to the MHRA?
No confirmed UK submission had been published as of June 2026. MHRA review typically takes around 210 days once a Marketing Authorisation Application is filed.